Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 25c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.27), $0.25 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $4.29 million versus the consensus estimate of $4.65 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Capitol Federal Financial names William Skrobacz Jr. as president
• Cintas beats estimates but stock edges lower